The FDA assessed the security and performance of atidarsagene autotemcel based upon knowledge from 37 youngsters who received atidarsagene autotemcel in two one-arm, open-label scientific trials and in an expanded obtain method.[7] Children who acquired therapy with atidarsagene autotemcel were compared to untreated little ones (organic record).[7]